The GCI recently released Beyond the Stories: Molecular Classification/ProMisE. In this video, clinician-researchers Dr. Jessica McAlpine and Dr. Amy Jamieson, and patient partners Stephani and Margaret discuss the life-changing endometrial cancer molecular classification tool that is ProMisE.
ProMisE stands for Proactive Molecular risk classifier for Endometrial cancer and was developed by a Vancouver-based research team led by Dr. Jessica McAlpine. This molecular classification system identifies four distinct molecular subtypes of endometrial cancer–POLE mutated, mismatch repair deficient, p53 abnormal, and p53wt/NSMP (no specific molecular profile). Identification of the tumor’s molecular profile can help inform prognosis and identify effective treatment plans for individual patients. It also helps circumvent some ambiguities that may be encountered in traditional histological classification methods (grading and histotype assignment), thus improving consistency in categorization.
Molecular classification tools, such as ProMisE, are a hallmark of the new age of precision medicine. Through accurate classification and risk stratification by ProMisE, patients are more likely to get the care they need, avoiding overtreatment and undertreatment.
The Vancouver-based team behind ProMisE is currently working to broaden the impact of molecular classification; investigating new ways to improve triage, further stratification within molecular subtypes, novel treatments, and the potential for artificial intelligence applications on pathologic images to add refinement. This exciting work recently received funding from the TFRI Project Grant Program 2023.
To learn more about the positive impact ProMisE is having on endometrial cancer care, please check out Beyond the Stories: Molecular Classification/ProMisE.
This episode officially marks the end of the Beyond the Stories Video Series. Since our launch in 2021, we have launched four incredible videos designed to share timely evidence-based information on the diagnosis, prevention, treatment, and survivorship of gynecologic cancers.
Advancements in Hereditary Cancer Research
Opportunistic Salpingectomy as a Strategy for Ovarian Cancer Prevention
A Conversation on Vulvar Cancer
Molecular Classification/ ProMisE
All of this was made possible thanks to funding from Michael Smith Health Research BC. We would also like to extend a massive thank you to the BC Women’s Health Foundation, VGH & UBC Hospital Foundation, BC Cancer Foundation, and the UBC Faculty of Medicine for supporting this project. Finally, we would also like to thank all our wonderful clinicians, researchers, and patient partners who participated in this project.